We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bank of Montreal (BMO) Down 3.8% Despite Q3 Earnings Rise
Read MoreHide Full Article
Bank of Montreal (BMO - Free Report) released third-quarter fiscal 2019 (ended Jul 31) results earlier this week. Adjusted net income was C$1.58 billion ($1.19 billion), up 1% year over year.
Results were primarily driven by rise in net interest income and non-interest income. Moreover, higher loans and deposits were tailwinds.
However, rise in expenses and weak trading performance were the undermining factors. Also, provisions increased substantially during the quarter. Perhaps these concerns weighed on investors’ sentiments and the stock declined 3.8% on the NYSE since the release of the results.
After considering non-recurring items, net income was C$1.56 billion ($1.17 billion), up 1% from the prior-year quarter.
Revenues & Expenses Up
Total revenues (on an adjusted basis), net of insurance claims, commissions and changes in policy benefit liabilities (CCPB), amounted to C$5.78 billion ($4.35 billion), up 5% year over year.
Net interest income grew 12% year over year to C$3.22 billion ($2.42 billion). Non-interest income came in at C$3.45 billion ($2.60 billion), increasing 18%.
Adjusted non-interest expenses increased 4% year over year to C$3.46 billion ($2.60 billion).
Efficiency ratio, net of CCPB, was 59.9%, down from 60.1% as of Jul 31, 2018. Fall in efficiency ratio indicates improvement in profitability.
Provision for credit losses jumped 65% year over year to C$306 million ($230.4 million).
Loans & Deposits Rise
Total assets increased 1% from the prior quarter to C$839.2 billion ($636 billion) as of Jul 31, 2019. Further, total net loans were up 1% sequentially to C$417.8 ($316.6 billion) and total deposits rose nearly 1% to C$553.4 billion ($419.4 billion).
Strong Profitability & Capital Ratios
Return on equity, as adjusted, came in at 13.5% in the reported quarter, down from 15.0% from Jul 31, 2018 level.
As of Jul 31, 2019, common equity Tier I ratio was 11.4%, on par with Jul 31, 2018 level. Tier I capital ratio was 13.0% compared with 12.9% a year ago.
Our Viewpoint
Bank of Montreal’s focus and efforts remain aligned with its organic and inorganic growth strategies, and are expected to boost revenues, going forward. Nevertheless, mounting expenses continue to strain the company’s profitability.
Bank Of Montreal Price, Consensus and EPS Surprise
Canadian Imperial Bank of Commerce (CM - Free Report) reported decent third-quarter fiscal 2019 (ended Jul 31) results. Adjusted earnings per share were C$3.10, up 1% from the prior-year quarter.
Royal Bank of Canada’s (RY - Free Report) third-quarter fiscal 2019 (ended Jul 31, 2019) net income was C$3.3 billion ($2.5 billion), up 5% from the prior-year quarter.
The Bank of Nova Scotia (BNS - Free Report) reported third-quarter fiscal 2019 (ended Jul 31) adjusted net income of C$2.5 billion ($1.9 billion), up 9% year over year. Results exclude acquisition- and divestiture-related costs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Bank of Montreal (BMO) Down 3.8% Despite Q3 Earnings Rise
Bank of Montreal (BMO - Free Report) released third-quarter fiscal 2019 (ended Jul 31) results earlier this week. Adjusted net income was C$1.58 billion ($1.19 billion), up 1% year over year.
Results were primarily driven by rise in net interest income and non-interest income. Moreover, higher loans and deposits were tailwinds.
However, rise in expenses and weak trading performance were the undermining factors. Also, provisions increased substantially during the quarter. Perhaps these concerns weighed on investors’ sentiments and the stock declined 3.8% on the NYSE since the release of the results.
After considering non-recurring items, net income was C$1.56 billion ($1.17 billion), up 1% from the prior-year quarter.
Revenues & Expenses Up
Total revenues (on an adjusted basis), net of insurance claims, commissions and changes in policy benefit liabilities (CCPB), amounted to C$5.78 billion ($4.35 billion), up 5% year over year.
Net interest income grew 12% year over year to C$3.22 billion ($2.42 billion). Non-interest income came in at C$3.45 billion ($2.60 billion), increasing 18%.
Adjusted non-interest expenses increased 4% year over year to C$3.46 billion ($2.60 billion).
Efficiency ratio, net of CCPB, was 59.9%, down from 60.1% as of Jul 31, 2018. Fall in efficiency ratio indicates improvement in profitability.
Provision for credit losses jumped 65% year over year to C$306 million ($230.4 million).
Loans & Deposits Rise
Total assets increased 1% from the prior quarter to C$839.2 billion ($636 billion) as of Jul 31, 2019. Further, total net loans were up 1% sequentially to C$417.8 ($316.6 billion) and total deposits rose nearly 1% to C$553.4 billion ($419.4 billion).
Strong Profitability & Capital Ratios
Return on equity, as adjusted, came in at 13.5% in the reported quarter, down from 15.0% from Jul 31, 2018 level.
As of Jul 31, 2019, common equity Tier I ratio was 11.4%, on par with Jul 31, 2018 level. Tier I capital ratio was 13.0% compared with 12.9% a year ago.
Our Viewpoint
Bank of Montreal’s focus and efforts remain aligned with its organic and inorganic growth strategies, and are expected to boost revenues, going forward. Nevertheless, mounting expenses continue to strain the company’s profitability.
Bank Of Montreal Price, Consensus and EPS Surprise
Bank Of Montreal price-consensus-eps-surprise-chart | Bank Of Montreal Quote
Bank of Montreal currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Canadian Banks
Canadian Imperial Bank of Commerce (CM - Free Report) reported decent third-quarter fiscal 2019 (ended Jul 31) results. Adjusted earnings per share were C$3.10, up 1% from the prior-year quarter.
Royal Bank of Canada’s (RY - Free Report) third-quarter fiscal 2019 (ended Jul 31, 2019) net income was C$3.3 billion ($2.5 billion), up 5% from the prior-year quarter.
The Bank of Nova Scotia (BNS - Free Report) reported third-quarter fiscal 2019 (ended Jul 31) adjusted net income of C$2.5 billion ($1.9 billion), up 9% year over year. Results exclude acquisition- and divestiture-related costs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>